SurvivorNet
Jeffrey Zonder, M.D., medical oncologist, leader of the Multiple Myeloma and Amyloidosis Multidisciplinary Team (MDT) and member of the Hematology Oncology MDT at Karmanos, comments on Minimal Residual Disease (MRD) testing. The multiple myeloma survivor the article refers to had MRD testing, which is a test that identifies if there are any cancer cells left after chemotherapy or other cancer treatments.
Read the article here.